Press Releases

GRAIL, AccessHope Collaborate to Optimize Patient and Healthcare Provider Experience for Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test

GRAIL has announced that it is joining forces with AccessHope™ to offer a world-class service experience to people who use Galleri™, GRAIL’s first-of-kind multi-cancer early detection blood test. This collaboration is part of GRAIL’s effort to help patients and their healthcare providers achieve favorable outcomes by making the test experience, from blood draw to cancer care, as seamless as possible. AccessHope, a company that provides cancer expertise to employers and their healthcare partners, will offer Galleri users coordination services during the test experience, including access to...

GRAIL Announces First Health System to Offer Galleri, Novel Multi-Cancer Early Detection Blood Test

GRAIL today announced a partnership with the health system Providence to offer Galleri, GRAIL’s multi-cancer early detection blood test. Providence, based in Renton, Wash., will offer Galleri as a complement to recommended single cancer screening tests. Providence will initially deploy Galleri at its California, Washington, and Oregon points of care, and the test could eventually be available across Providence’s entire seven-state footprint that includes more than 50 hospitals and nearly 1,100 health clinics serving 5 million patients. Providence’s aim is to pursue effective ways to identify...

Truveris Expands Leadership Team With Key Appointments

Truveris, a digital health company focused on reducing costs and improving access in pharmacy, announced that it has bolstered its leadership team with several key hires and internal appointments. Under the leadership of CEO Jeff Eberle, Truveris has assembled a seasoned team of industry veterans to drive innovation and fuel the company’s rapid growth trajectory. The expansion of the leadership team demonstrates Truveris’ deep commitment to serve as a leader in driving transparency, affordability, and access across the pharmacy supply chain. “At Truveris, we are laser-focused on...

Hims & Hers Health, Inc. Closes Business Combination and Wil Begin Trading on the New York Stock Exchange

Hims & Hers Health Inc (“Hims & Hers”), a multi-specialty telehealth platform, announced that it has closed its business combination with Oaktree Acquisition Corp., a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management. The transaction, which was approved by Oaktree’s shareholders on January 19, 2021, uniquely positions Hims & Hers to lead the rapidly growing telehealth industry. Beginning January 21, 2021, the company's shares of Class A common stock will trade on the New York Stock Exchange under the symbol “HIMS,”...

Aledade Raises $100 Million Series D to Help More Primary Care Practices Thrive in Value-Based Care

Aledade recently closed a $100 million Series D funding round following a year of significant growth for its national network of risk-taking primary care practices. Returning investor Meritech Capital led the round, which included new growth investors Tiger Global Management and IVP, and returning investor OMERS Growth Equity. “Working in partnership with hundreds of amazing primary care practices, Aledade ACOs have help achieve better health outcomes for more than a million patients through risk-taking contracts across all types of payers, with remarkable growth in Medicare Advantage,”...

Kyruus Enables Online Scheduling for COVID-19 Vaccine Visits and Facilitates More Than 100,000 Appointments in the First Month

Kyruus announced that it has expanded its patient access platform to enable customers to offer online consumer scheduling for COVID-19 vaccine visits. The vaccine scheduling capabilities are available within the company’s award-winning online scheduling solution. Almost 10 health systems have already activated vaccine scheduling with Kyruus, cumulatively booking more than 100,000 appointments in the first month alone. Kyruus enables healthcare organizations to offer intuitive online scheduling with its Kyruus ProviderMatch for Consumers solution for websites and mobile apps. Coupling rich, search engine-optimized profiles with a dynamic care...

Augmedix Launches Tech-Enabled Service Within Emergency Departments to Provide Real-Time Support and Optimize Clinician Workflows

Augmedix, a provider of remote medical documentation and live clinical support, is announcing a rollout of a tech-enabled medical documentation service powered by virtual scribes and created specifically for busy Emergency Department (ED) environments, Augmedix trains remotely located scribes in emergency medicine documentation to alleviate the administrative burden for clinicians, which is especially important today as these providers are on the front lines of the COVID crisis. The virtual scribes use proprietary Augmedix technology to ensure consistent, accurate documentation, which adds value and potential return on...

Accolade to Acquire 2nd.MD

Accolade, a company that provides personalized solutions that help people better understand, navigate, and use the healthcare system and their workplace benefits, has signed a definitive agreement to acquire Innovation Specialists, LLC (d/b/a 2nd.MD), a leading expert medical opinion and decision support company. Healthcare utilization is expected to rise significantly in 2021 due to the effects of the COVID-19 pandemic. With that in mind, the integration of 2nd.MD with Accolade’s health and benefit solutions and clinical service offerings will make the healthcare experience simpler for employees...

GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease

GRAIL today announced a collaboration with global biopharmaceutical companies Amgen, AstraZeneca, and Bristol Myers Squibb to evaluate GRAIL’s methylation-based technology for the detection of minimal residual disease (MRD). Cancer MRD testing is used in clinical and research applications to detect the presence or absence of residual disease. Many MRD tests available today for solid tumors require tissue samples and development of patient-specific assays, which can result in potential delay in treatment decisions. GRAIL’s targeted methylation platform could enable a blood-based MRD detection assay for solid tumors...

GRAIL Confirms Q2 2021 Introduction of Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test

GRAIL has confirmed that it expects to introduce Galleri™, its multi-cancer early detection blood test, in the second quarter of 2021. In December 2020, GRAIL completed the enrollment of PATHFINDER, a prospective, 6,600-participant multi-site interventional study conducted under a U.S. Food and Drug Administration Investigational Device Exemption application to evaluate the implementation of Galleri in clinical practice. PATHFINDER has completed its second planned independent Data and Safety Monitoring Board review. GRAIL expects to present initial results from PATHFINDER, and additional clinical validation from GRAIL’s foundational Circulating Cell-free...